Regencell Bioscience Holdings (Regencell Bioscience Holdings) Debt-to-EBITDA : -0.08 (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Regencell Bioscience Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.44 Mil. Regencell Bioscience Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.03 Mil. Regencell Bioscience Holdings's annualized EBITDA for the quarter that ended in Jun. 2023 was $-5.69 Mil. Regencell Bioscience Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -0.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Regencell Bioscience Holdings's Debt-to-EBITDA or its related term are showing as below:

RGC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -5.33 Med: -2.72 Max: -0.07
Current: -0.07

During the past 5 years, the highest Debt-to-EBITDA Ratio of Regencell Bioscience Holdings was -0.07. The lowest was -5.33. And the median was -2.72.

RGC's Debt-to-EBITDA is ranked worse than
100% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs RGC: -0.07

Regencell Bioscience Holdings Debt-to-EBITDA Historical Data

The historical data trend for Regencell Bioscience Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Debt-to-EBITDA Chart

Regencell Bioscience Holdings Annual Data

Trend

Jun19

Jun20

Jun21

Jun22

Jun23

Debt-to-EBITDA

-5.33

-3.82

-2.72

-0.11

-0.08

Regencell Bioscience Holdings Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-EBITDA	Get a 7-Day Free Trial				-1.84	-	-0.10	-	-0.08

Competitive Comparison of Regencell Bioscience Holdings's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regencell Bioscience Holdings's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Debt-to-EBITDA falls into.

Regencell Bioscience Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Regencell Bioscience Holdings's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.438	+	0.025)	/	-5.504
	=	-0.08

Regencell Bioscience Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.438	+	0.025)	/	-5.688
	=	-0.08

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2023) EBITDA data.

Regencell Bioscience Holdings (NAS:RGC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Regencell Bioscience Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG

Website

https://www.regencellbioscience.com

Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.